RCUS - Arcus Biosciences, Inc.

NYSE - NYSE Delayed Price. Currency in USD
7.38
+0.27 (+3.80%)
At close: 4:02PM EDT
Stock chart is not supported by your current browser
Previous Close7.11
Open7.15
Bid7.40 x 800
Ask8.00 x 900
Day's Range7.08 - 7.60
52 Week Range6.30 - 16.06
Volume157,799
Avg. Volume185,298
Market Cap328.668M
Beta (3Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-1.26
Earnings DateAug 6, 2019 - Aug 6, 2019
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.60
Trade prices are not sourced from all markets
  • American City Business Journals

    It’s not just Bloom Energy: Half of last year’s Bay Area IPO stocks are underwater

    Half of the 34 businesses from the region that debuted on Wall Street in 2018 are now trading below their initial offering price, and three have experienced bigger percentage drops than Bloom.

  • Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates
    Zacks

    Arcus Biosciences, Inc. (RCUS) Reports Q2 Loss, Misses Revenue Estimates

    Arcus Biosciences, Inc. (RCUS) delivered earnings and revenue surprises of -72.97% and -61.45%, respectively, for the quarter ended June 2019. Do the numbers hold clues to what lies ahead for the stock?

  • Business Wire

    Arcus Biosciences Announces Second Quarter 2019 Financial Results and Recent Corporate Updates

    - Progressing our lead program, AB928, a potential best-in-class dual A2a/A2b receptor antagonist, into multiple dose-expansion cohorts in 2H19, including metastatic castration res

  • Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss
    Zacks

    Infinity (INFI) Q2 Loss Wider Than Expected, Sales Miss

    Infinity (INFI) posts wider-than-expected loss in the second quarter of 2019 and misses sales estimates.

  • Business Wire

    Arcus Biosciences to Present at Upcoming Investor Conferences

    Arcus Biosciences, Inc. , a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that members of the managemen

  • Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q2 Earnings Expected to Decline
    Zacks

    Earnings Preview: Arcus Biosciences, Inc. (RCUS) Q2 Earnings Expected to Decline

    Arcus Biosciences, Inc. (RCUS) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

  • If You Had Bought Arcus Biosciences (NYSE:RCUS) Stock A Year Ago, You'd Be Sitting On A 30% Loss, Today
    Simply Wall St.

    If You Had Bought Arcus Biosciences (NYSE:RCUS) Stock A Year Ago, You'd Be Sitting On A 30% Loss, Today

    Investors can approximate the average market return by buying an index fund. Active investors aim to buy stocks that...

  • Benzinga

    The Daily Biotech Pulse: Verrica Rallies, Aclaris Flunked Hair Loss Study, 3 Biotechs To IPO

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech stocks hitting 52-week highs on June 26) Odonate Therapeutics Inc (NASDAQ: ODT ) Down In The ...

  • Business Wire

    Arcus Biosciences Appoints Global Immuno-Oncology Commercial Leader, Eric Hoefer as Chief Commercial Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that Eric Hoefer has joined the Company as Chief Commercial Officer. Mr. Hoefer will oversee all aspects of the Company’s global commercial strategy and operations as the Company works to ensure that it most efficiently leverages the clinical and market development opportunities for its therapeutic candidates.

  • Business Wire

    Arcus Biosciences to Provide a Mid-Year Update on Clinical and Preclinical Programs

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies, today announced that the Company will host a conference call and live webcast on Tuesday, June 25, 2019, at 1:30 p.m. Pacific Time/4:30 p.m. Eastern Time to provide a mid-year update on its clinical and preclinical programs. Following the live webcast, a replay will be available on the Company’s website for approximately 30 days. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer therapies. Arcus has several programs targeting important oncology/immuno-oncology pathways, including a dual adenosine receptor antagonist, AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody, AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • GuruFocus.com

    Arcus Biosciences Inc (RCUS) CEO Terry J Rosen Bought $172,382 of Shares

    CEO of Arcus Biosciences Inc (NYSE:RCUS) Terry J Rosen bought 21,738 shares of RCUS on 06/06/2019 at an average price of $7.93 a share.

  • Business Wire

    Arcus Biosciences to Present Preliminary Data from the Ongoing Phase 1 Dose-Escalation Trials of AB928 in Combination with Chemotherapy or AB122 at the 2019 ASCO Annual Meeting

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the Company will be presenting preliminary data from the ongoing Phase 1 dose-escalation trials of AB928, a potential best-in-class dual A2a/A2b receptor antagonist, in a poster session at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place in Chicago, IL, from May 31-June 4, 2019. The activation of these receptors by adenosine interferes with the activity of key populations of immune cells and inhibits an optimal anti-tumor immune response.

  • Business Wire

    Arcus Biosciences to Present at the Jefferies 2019 Global Healthcare Conference

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that Terry Rosen, Ph.D., Chief Executive Officer, will present at the Jefferies 2019 Global Healthcare Conference on Tuesday, June 4, 2019 at 4 pm ET at the Grand Hyatt, in New York, NY. Arcus Biosciences is a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies. Arcus has several programs targeting important immuno-oncology pathways, including a dual adenosine receptor antagonist AB928, which is in a Phase 1/1b program to evaluate AB928 in combination with other agents in multiple tumor types, and an anti-PD-1 antibody AB122, which is being evaluated in a Phase 1 trial and is being tested in combination with Arcus’s other product candidates.

  • Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?
    Insider Monkey

    Is Arcus Biosciences, Inc. (RCUS) A Good Stock To Buy?

    Is Arcus Biosciences, Inc. (NYSE:RCUS) a good bet right now? We like to analyze hedge fund sentiment before doing days of in-depth research. We do so because hedge funds and other elite investors have numerous Ivy League graduates, expert network advisers, and supply chain tipsters working or consulting for them. There is not a shortage […]

  • Infinity (INFI) Earnings and Sales Miss Estimates in Q1
    Zacks

    Infinity (INFI) Earnings and Sales Miss Estimates in Q1

    Infinity (INFI) posts wider-than-expected loss in the first quarter of 2019. Sales miss estimates in the quarter.

  • Zacks

    Trade Anxieties Return with a Vengeance

    Trade Anxieties Return with a Vengeance

  • Business Wire

    Arcus Biosciences Announces First Quarter 2019 Financial Results and Recent Corporate Updates

    - Selected 150 mg for the dose expansion trial for AB928, the Company’s dual A2a/A2b receptor antagonist, in combination with AB122, the Company’s anti-PD-1 antibody

  • Business Wire

    Arcus Biosciences Appoints William Grossman, M.D., Ph.D., Chief Medical Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced that William Grossman, M.D., Ph.D. has joined the Company as Chief Medical Officer. Dr. Grossman will oversee all aspects of the Company’s global clinical development strategy and operations. “We are pleased to have Dr. Grossman join Arcus during this seminal period in the advancement and expansion of our clinical development programs,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.

  • Business Wire

    Arcus Biosciences and Strata Oncology Announce Clinical Development Collaboration for Anti-PD-1 Antibody AB122

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, and Strata Oncology, Inc. (“Strata”), a precision oncology company, today announced that the companies have entered into a clinical development collaboration utilizing Strata’s precision drug development platform and proprietary biomarkers to evaluate AB122, Arcus’s clinical-stage anti-PD-1 antibody, in a basket trial including tumor types that are generally not responsive to anti-PD-1 therapy. As part of this partnership, Arcus will gain access to Strata’s drug development platform, featuring leading capabilities to design and conduct transformative precision therapy studies.

  • Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?
    Zacks

    Arcus (RCUS) to Report Q1 Earnings: What's in the Cards?

    Arcus (RCUS) is expected to provide an update on its pipeline with the release of its first-quarter 2019 results

  • Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised
    Zacks

    Alexion (ALXN) Q1 Earnings Beat Estimates, Guidance Raised

    Alexion (ALXN) beats earnings and sales estimates in the first quarter of 2019 and raises guidance for the year.

  • What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)?
    Simply Wall St.

    What Kind Of Shareholders Own Arcus Biosciences, Inc. (NYSE:RCUS)?

    If you want to know who really controls Arcus Biosciences, Inc. (NYSE:RCUS), then you'll have to look at the makeup of its share registry. Insiders often own a large chunk of younger, smaller, companies while huge companies tend to...

  • Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?
    Zacks

    Arcus Biosciences, Inc. (RCUS) Shares March Higher, Can It Continue?

    As of late, it has definitely been a great time to be an investor in Arcus Biosciences, Inc. (RCUS).

  • Business Wire

    Arcus Biosciences Appoints Rekha Hemrajani as Chief Operating and Financial Officer

    Arcus Biosciences, Inc. (RCUS), a clinical-stage biopharmaceutical company focused on creating innovative cancer immunotherapies, today announced the appointment of Rekha Hemrajani as Chief Operating and Financial Officer. Ms. Hemrajani will be responsible for several key areas, including finance, investor relations, corporate communications, business and corporate development, strategic planning and human resources. “We are thrilled to welcome Rekha as a key member of our senior leadership team, as we enter an exciting period in Arcus’s development with multiple Phase 1 readouts for AB928, our dual A2a/A2b receptor antagonist, AB154, our anti-TIGIT antibody, and AB680, our small-molecule CD73 inhibitor,” said Terry Rosen, Ph.D., Chief Executive Officer of Arcus.

  • Infinity Inks Deal With Roche for Phase II Study of IPI-549
    Zacks

    Infinity Inks Deal With Roche for Phase II Study of IPI-549

    Shares of Infinity (INFI) rise after the company inks deal with Roche to initiate a phase II MARIO-3 study on IPI-549. Per the deal, Roche will supply Tecentriq (atezolizumab) to Infinity.